Loading...
XSTO
IMMNOV
Market cap11mUSD
May 28, Last price  
0.36SEK
1D
0.70%
1Q
-8.40%
Jan 2017
-99.61%
IPO
-98.72%
Name

Immunovia AB (publ)

Chart & Performance

D1W1MN
P/E
—
P/S
118.36
EPS
—
Div Yield, %
—
Shrs. gr., 5y
31.40%
Rev. gr., 5y
21.20%
Revenues
931k
-40.89%
208,8121,178,634359,165205,193177,284148,963332,595356,000362,000844,0001,145,0001,575,000931,000
Net income
-77m
L-75.26%
-258,905-1,596,419-8,859,089-7,383,680-14,723,222-45,232,200-86,538,641-114,521,000-147,451,000-157,398,000-145,034,000-309,439,000-76,541,000
CFO
-97m
L-34.21%
0-414,310-8,290,625-2,843,341-11,866,824-46,317,954-84,111,307-91,952,000-120,704,000-152,648,000-175,582,000-147,057,000-96,753,000
Earnings
Jun 19, 2025

Profile

Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
URL
https://immunovia.com/
IPO date
Dec 01, 2015
Employees
39
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
931
-40.89%
1,575
37.55%
1,145
35.66%
Cost of revenue
41,098
52,113
Unusual Expense (Income)
NOPBT
931
(39,523)
(50,968)
NOPBT Margin
100.00%
Operating Taxes
(23,058)
Tax Rate
NOPAT
931
(39,523)
(27,910)
Net income
(76,541)
-75.26%
(309,439)
113.36%
(145,034)
-7.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
52,411
121,243
639
BB yield
-116.19%
-87.41%
-0.10%
Debt
Debt current
2,499
4,874
Long-term debt
6,073
70,274
Deferred revenue
Other long-term liabilities
Net debt
(25,318)
(68,216)
(34,393)
Cash flow
Cash from operating activities
(96,753)
(147,057)
(175,582)
CAPEX
(1,061)
(1,624)
Cash from investing activities
3,197
(1,624)
Cash from financing activities
44,812
114,743
(5,107)
FCF
14,094
(6,763)
(29,260)
Balance
Cash
25,318
76,788
106,041
Long term investments
3,500
Excess cash
25,271
76,709
109,484
Stockholders' equity
(1,130,280)
(1,069,489)
(748,260)
Invested Capital
1,141,929
1,140,766
1,029,637
ROIC
0.08%
ROCE
7.99%
EV
Common stock shares outstanding
82,614
78,368
24,386
Price
0.55
-69.15%
1.77
-93.27%
26.30
-64.93%
Market cap
45,107
-67.48%
138,712
-78.37%
641,350
-64.93%
EV
19,789
70,496
631,263
EBITDA
931
102,196
(26,055)
EV/EBITDA
21.26
0.69
Interest
1,860
1,166
1,600
Interest/NOPBT
199.79%